Diabetes & Endocrinology – Page 5

Impact of Dietary Patterns on the Progression of Chronic Kidney Disease in Cardio-Metabolic Disorders: Insights from Multi-State Models in a Large UK Cohort

By MedXY 10/19/2025

This study reveals that adherence to the American Heart Association diet significantly reduces CKD progression risk from cardio-metabolic disorders, underscoring its role in early intervention strategies.

Diabetes & Endocrinology Internal Medicine Specialties

Revisiting Obesity Classification: Insights from a Population-Based Survey in Peru Using New Clinical Frameworks

By MedXY 10/19/2025

This review examines a landmark Peruvian study applying new obesity definitions that incorporate clinical dysfunction and adiposity measures beyond BMI, revealing substantial underdiagnosis with traditional approaches and ethnic variation in fat distribution.

Diabetes & Endocrinology General Surgery news

Long-Term Comparative Outcomes of Gastric Bypass and Sleeve Gastrectomy in Type 2 Diabetes: Evidence from a Swedish Matched Cohort Study

By MedXY 10/19/2025

A Swedish nationwide study reveals Roux-en-Y gastric bypass yields superior long-term benefits in type 2 diabetes remission and reduced mortality compared to sleeve gastrectomy, despite higher risks of nutritional deficiencies and psychiatric complications.

Diabetes & Endocrinology news Public Health Specialties

Bridging the Gaps in Global Diabetes Care: Insights from Two Decades of the Global Burden of Disease Study

By MedXY 10/19/2025

A comprehensive analysis reveals ongoing challenges in diabetes diagnosis, treatment, and glycaemic control worldwide, highlighting the urgent need for enhanced care strategies, especially in low- and middle-income regions.

Diabetes & Endocrinology Specialties

Enhanced Weight Reduction with Once-Weekly Semaglutide 7.2 mg in Obesity Management: Insights from the STEP UP Phase 3b Trial

By MedXY 10/18/2025

The STEP UP trial demonstrates that once-weekly semaglutide 7.2 mg significantly improves weight loss outcomes versus 2.4 mg and placebo in adults with obesity, with a manageable safety profile.

Diabetes & Endocrinology Internal Medicine Specialties

Monlunabant Shows Promise for Weight Loss in Obesity and Metabolic Syndrome: A Phase 2A Trial Review

By MedXY 10/18/2025

This phase 2a trial demonstrates that monlunabant induces significant weight loss across various doses in obese adults with metabolic syndrome, with dose-dependent adverse events highlighting the need for further safety evaluation.

Diabetes & Endocrinology news Oncology

Enhancing Prognostication in Papillary Thyroid Cancer: Integrating BRAF and TERT Mutations into the AJCC Staging System

By MedXY 10/15/2025

Incorporating BRAF and TERT promoter mutations into the AJCC classification for papillary thyroid cancer significantly improves mortality risk prediction, refining patient stratification beyond traditional clinical staging.

Diabetes & Endocrinology Ophthalmology Specialties

IBI311, an IGF-1R Inhibitor, Shows Promising Results for Active Thyroid Eye Disease in Chinese Patients: Insights from the RESTORE-1 Trial

By MedXY 10/15/2025

The RESTORE-1 phase 3 trial demonstrates that IBI311 significantly improves proptosis and inflammation in Chinese patients with active thyroid eye disease, with a favorable safety profile.

Diabetes & Endocrinology news Urology

Obesity Interventions and Male Fertility: Unraveling the Effects of Weight Loss on Reproductive Health

By MedXY 10/12/2025

This systematic review and meta-analysis evaluates the effects of obesity interventions—lifestyle modification, pharmacotherapy, and bariatric surgery—on male fertility, highlighting improvements with lifestyle changes and limited benefits from surgical weight loss.

Diabetes & Endocrinology news OB/GYN & Women's Health Specialties

Evaluating Selenium Supplementation in Gestational Diabetes Mellitus: Insights from a Systematic Review and Meta-Analysis

By MedXY 10/12/2025

Selenium supplementation at 200 µg/d may reduce fasting plasma glucose and newborn hyperbilirubinemia risk in gestational diabetes without significantly altering lipid profiles, highlighting potential but limited benefits requiring further research.

Diabetes & Endocrinology Specialties

Optimizing Antithymocyte Globulin Dose for Preserving Beta-Cell Function in Recent-Onset Type 1 Diabetes: Insights from the MELD-ATG Trial

By MedXY 10/11/2025

The MELD-ATG phase 2 trial identifies low-dose antithymocyte globulin as an effective and safe intervention to reduce beta-cell loss in young people with recent-onset type 1 diabetes, highlighting a potential disease-modifying therapy.

Diabetes & Endocrinology news Pediatrics

Tirzepatide Shows Promising Efficacy and Safety in Managing Youth-Onset Type 2 Diabetes: Insights from the SURPASS-PEDS Trial

By MedXY 10/10/2025

The phase 3 SURPASS-PEDS trial demonstrates that tirzepatide significantly improves glycaemic control and reduces BMI in children and adolescents with type 2 diabetes, with a safety profile consistent with adult studies.

Diabetes & Endocrinology news OB/GYN & Women's Health Specialties

Evaluating Myo-Inositol Supplementation for Preventing Pregnancy Complications in PCOS: Insights from a Robust Randomized Trial

By MedXY 10/10/2025

A large randomized clinical trial found that myo-inositol supplementation during pregnancy in individuals with PCOS did not significantly reduce rates of gestational diabetes, preeclampsia, or preterm birth compared to placebo.

Diabetes & Endocrinology General Surgery news

Patterns and Predictors of GLP-1 Agonist Use After Bariatric Surgery in US Adults

By MedXY 10/10/2025

A large US cohort study reveals that 14% of bariatric surgery patients start GLP-1 receptor agonists postoperatively, with higher use seen among women, sleeve gastrectomy recipients, and those with greater BMI regain.

Diabetes & Endocrinology Gastroenterology news

Noninvasive Biomarkers Track Semaglutide Efficacy in Metabolic Dysfunction-Associated Steatohepatitis

By MedXY 10/09/2025

A phase 2b trial demonstrates that several noninvasive tests reliably reflect treatment response to semaglutide in patients with metabolic dysfunction-associated steatohepatitis, correlating with histologic improvements over 72 weeks.

Diabetes & Endocrinology Family Medicine & Nutrition news Specialties

Preserving Bone Quality in Older Adults with Obesity Through Lifestyle Intervention: Insights from the LIMB-Q Trial

By MedXY 09/29/2025

The LIMB-Q trial demonstrates that intensive lifestyle interventions combining weight management and exercise preserve bone quality in older adults with obesity, despite significant weight loss, highlighting a promising approach for mitigating osteoporosis risk during aging.

Diabetes & Endocrinology news Ophthalmology Specialties

Acute Angle Closure Incidence in a Large Countywide Safety Net Teleretinal Screening Program: Safety of Pharmacologic Dilation in Diabetic Retinopathy Screening

By MedXY 09/28/2025

This review synthesizes evidence on the incidence of acute angle closure (AAC) following pharmacologic pupillary dilation in a large teleretinal screening program, confirming the very low risk and supporting dilation safety in diverse populations.

Clinical Updates Diabetes & Endocrinology news Specialties

Cutaneous Presentation of Hyperthyroidism in a Middle-aged Female: A Case Report

By MedXY 09/28/2025

A 45-year-old female presented with pruritic skin lesions and weight loss, diagnosed with hyperthyroidism manifesting cutaneous symptoms. Treatment with antithyroid medication led to symptom resolution.

Cardiology Diabetes & Endocrinology Specialties

Transthyretin Cardiac Amyloidosis in Older Black and Hispanic Patients with Heart Failure: Prevalence, Genetics, and Clinical Implications

By MedXY 09/27/2025

A prospective study reveals transthyretin cardiac amyloidosis (ATTR-CA) affects a significant proportion of older Black patients with heart failure, especially men over 75, with nearly half linked to the V142I genetic variant. Hispanic prevalence is lower but still notable.

Diabetes & Endocrinology news Specialties

Orforglipron: A Promising Oral GLP-1 Receptor Agonist for Long-Term Obesity Management

By MedXY 09/27/2025

Orforglipron, a novel oral GLP-1 receptor agonist, demonstrated significant and sustained weight reduction in obese adults without diabetes in a 72-week phase 3 trial, with a tolerable safety profile consistent with existing GLP-1 therapies.